-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82

Benzinga·05/06/2026 19:49:04
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $80 to $82.